The Zhitong Finance App learned that Tianxing Healthcare (01609) rose by more than 7%. As of press release, it had risen 7.25% to HK$67.8, with a turnover of HK$17.4093 million.

According to the news, recently, Tianxing Medical announced that the company has received CE MDR certification for 15 types of products, including full-stitched anchors, full-stitched tabs, and arthroscopic surgical instruments, covering the six major joint fields of shoulder, knee, hip, elbow, wrist, and ankle. CITIC Construction Investment believes that the registration progress of the above products marks the company becoming the first sports medicine manufacturer in China to obtain CE MDR certification for all products. In addition, applications for registration of plasma surgery equipment, electrodes, full suture anchors, and suture products submitted by the company in the United Kingdom, Australia, Brazil, Singapore, Malaysia, Thailand and other countries have been approved and registered.

CITIC Construction Investment added that looking ahead to the second half of the year, the 2026 sports medicine procurement contract renewal pace was delayed from expectations, putting some pressure on the company's domestic revenue growth in the first half of the year. The bank expects the sports medicine collection contract renewal to be implemented in the fourth quarter of 2026, and the company's domestic revenue growth rate in the second half of the year is expected to increase compared to the first half of the year. The company continues to accelerate its overseas market layout. With the continuous improvement of overseas product registration certificates, it is expected to continue the trend of rapid growth in overseas revenue.